Jazz Pharmaceuticals (NASDAQ:JAZZ) Rating Reiterated by Truist Financial
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report)‘s stock had its “buy” rating reissued by Truist Financial in a research report issued on Wednesday, Benzinga reports. They currently have a $200.00 price target on the specialty pharmaceutical company’s stock. Truist Financial’s target price points to a potential upside of 61.16% from the company’s current price. JAZZ […]
More Stories
Canadians Increasingly Favor Economic Growth Over Environmental Stewardship in Energy Policy: Poll
By William Hetherington Canadians are increasingly prioritizing economic growth over environmental protection in energy policy decisions, with support for new...
Record 45 Million Americans Expected to Travel Over Memorial Day Weekend: AAA
By Mary Prenon Despite rising gas prices, more than 45 million Americans are expected to hit the road, fly, or...
Trump Says US–Iran Ceasefire on ‘Life Support’
By Jack Phillips President Donald Trump on Monday said that a weeks-long ceasefire with Iran is in jeopardy and suggested...
Why Americans Pay High Gas Prices Despite Record U.S. Oil Production and Exports
By Stephen Zogopoulos, USNN World News The Paradox at the Pump As of early May 2026, U.S. regular gasoline prices...
What Time Does Netflix Release Shows? Don’t Miss Another New Release
Many of us like to watch series and movies, but most of the time miss the new release, right? And...
Trump Calls Iran’s Response to Peace Proposal ‘Totally Unacceptable’
By Tom Gantert U.S. President Donald Trump on May 10 rejected Iran’s response to the latest peace proposal pitched by...